Opinion: Too Many Mitochondrial Genome Papers

And too few insights gleaned from them

Written byDavid R. Smith
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

The protist Euglena sp. (scale bar 25 µm)WIKIMEDIA, ROGELIO MORENOI just finished reviewing another mitochondrial genome paper. These days, the mitochondrial genome review requests are arriving faster than I can turn them out. Indeed, in 2014 alone, more than a thousand new mitochondrial genome sequences were deposited in GenBank—an almost 15 percent increase from the previous year.

Few would question the utility of mitochondrial DNA (mtDNA) as a genetic marker. But it is increasingly clear that sequencing mtDNA has become an easy route to peer-reviewed publications; at times, the pursuit of these publications is encumbering journal editors, referees, and the research infrastructure as a whole. Is publishing papers on mitochondrial genomes a relic of the “publish or perish” academic landscape? Should mtDNA sequences go directly into GenBank? Are we still gaining new and significant insights from mitochondrial genome data?

Importance of mtDNA

The first non-viral genome to be completely sequenced, in 1981, was human mtDNA, which built momentum towards a nuclear genome project. By the early 1990s, dozens of other mtDNAs had been decoded, including ones from land plants and protists, which ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies